SCHEMBL1144239

SCHEMBL1144239

O=Cc1c(Cl)[nH]c2cc(Cl)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.54
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PARP1 P09874 1/20 0.49
LMNA P02545 3/20 0.46
CA9 Q16790 2/20 0.44
CA12 O43570 1/20 0.44
PLK4 O00444 1/20 0.43
PLK1 P53350 1/20 0.43
DAO P14920 1/20 0.43
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
CYP2C9 P11712 1/20 0.42
MAPK1 P28482 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 2/20 0.42
GRIN2D O15399 3/20 0.41
GRIN3B O60391 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29878739 1.00 ALOX15 (0.54) ALOX15TP53SMN1; SMN2PARP1LMNA
SCHEMBL22898794 0.85 LMNA (0.51) ALOX15SMN1; SMN2PARP1LMNACA9
SCHEMBL29363428 0.85 LMNA (0.51) ALOX15SMN1; SMN2PARP1LMNACA9
SCHEMBL12571208 0.82 ALOX15 (0.58) ALOX15TP53SMN1; SMN2PARP1LMNA
SCHEMBL29952323 0.82 GSK3B (0.51) ALOX15CYP2C9
SCHEMBL28472387 0.82 ALOX15 (0.51) ALOX15TP53SMN1; SMN2PARP1LMNA
SCHEMBL24522311 0.78 ALDH1A1 (0.57) ALOX15SMN1; SMN2LMNAHPGDKDM4E
SCHEMBL31025899 0.78 ALOX15 (0.65) ALOX15LMNAHPGDKDM4EMEN1
SCHEMBL26323682 0.78 CDK1 (0.46) ALOX15PARP1KDM4EALDH1A1AHR
SCHEMBL29362992 0.78 ALDH1A1 (0.57) ALOX15SMN1; SMN2LMNAHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092744-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) 2024-03-21 US disclosed
CN-114981275-B Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-12-19 CN disclosed
EP-4273150-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd (CN) 2023-11-08 EP disclosed
CN-114981275-A Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2022-08-30 CN disclosed
WO-2022143489-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2022-07-07 WO disclosed
EP-2247575-B1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2016-03-23 EP disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-8211885-B2 Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-07-03 US disclosed
US-20090215741-A1 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
WO-2009095163-A2 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed
US-7547706-B2 1H-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use SANOFI-AVENTIS (FR) 2009-06-16 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed
US-20080125410-A1 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease SANOFI-AVENTIS (FR) 2008-05-29 US disclosed
EP-1874777-A1 H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE Sanofi-Aventis (FR) 2008-01-09 EP disclosed
US-20070203209-A1 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. 2007-08-30 US disclosed
WO-2007022501-A2 USEFUL INDOLE COMPOUNDS MICROBIA, INC. (US) 2007-02-22 WO disclosed
WO-2006111648-A1 H-PYRIMIDO[4,5-B]INDOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE SANOFI-AVENTIS (FR) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215741-A1 1H-Pyrimido[4,5-b]indole Derivatives, Their Preparation and Therapeutic Use IDO1, IDO2, TPH1 ALOX15 963/4885TP53 1049/4885SMN1; SMN2 901/4885
US-20080125410-A1 7-chloro-N,N-9-trimethyl-2-(6-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indole-4-carboxamide; ethyl 7-chloro-9-methyl-2-phenyl-9H-pyrimido[4,5-b]indole-4-carboxylate; 4-[(4-azetidin-1-yl)piperidin-1-ylcarbonyl]-7-chloro-9-methyl-2-phenyl-9H-pyrimido-[4,5-b]indole; Alzheimer's or Parkinson's disease PARK7, SNCA, PSEN2 ALOX15 3102/4885TP53 3083/4885SMN1; SMN2 436/4885
US-20240092744-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GOT2, HADH, CYP4A11 ALOX15 61/4885TP53 2179/4885SMN1; SMN2 3784/4885
US-20070203209-A1 Useful indole compounds TPH2, HRH2, HRH1 ALOX15 192/4885TP53 4056/4885SMN1; SMN2 2272/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 ALOX15 51/4885TP53 4734/4885SMN1; SMN2 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.